Key Highlights

  • ALMS shares traded down 56.90% intraday to $9.40, on Volume more than 18 times average.
  • The Phase 2b LUMUS trial of envudeucitinib did not meet its primary or secondary endpoints in the overall trial population.
  • A prespecified subgroup of patients with high interferon gene signature showed statistically significant responses on the primary endpoint and key secondary measures.
  • That subgroup was unexpectedly under-represented in the trial, reducing response rates across the overall population.
  • The company remains on track to file for regulatory approval of envudeucitinib in plaque psoriasis in the fourth quarter of 2026.

Lupus Trial Fails to Meet Primary Endpoint in Overall Population

Alumis (NASDAQ:ALMS) shares plunged in active trading after the company announced that its Phase 2b LUMUS trial of envudeucitinib for moderate-to-severe systemic lupus erythematosus did not meet its primary and secondary endpoints in the overall trial population. The trial enrolled 408 patients who received one of three envudeucitinib doses or placebo over 48 weeks.

Alumis is a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases. Its lead candidate, envudeucitinib, is an oral allosteric inhibitor of tyrosine kinase 2 designed to correct immune dysregulation across diseases driven by interferon and related inflammatory pathways.

Subgroup Data Offers a Silver Lining Despite the Overall Miss

A prespecified subgroup analysis of patients with high interferon gene signature showed strong, statistically significant responses, including on the trial's primary endpoint and several key secondary measures. That subgroup, which typically represents the majority of moderate-to-severe systemic lupus cases, was unexpectedly under-represented in the LUMUS trial, a mismatch that management said reduced response rates across the broader trial population. The company said it plans to engage regulators to discuss a Phase 3 program focused specifically on that subgroup.

Safety Profile Remained Favorable Throughout the Trial

Pharmacodynamic data from the trial confirmed dose-dependent target engagement, with the strongest suppression observed at the highest dose tested. Envudeucitinib was generally well tolerated in the study, with no new safety signals identified. Alumis carries a market Capitalization of roughly $1.17 billion following today's decline.

Psoriasis Program Remains on Track Despite the Lupus Setback

Despite the lupus trial miss, Alumis reaffirmed that it remains on track to submit a new drug application for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026, a program built on positive Phase 3 results reported previously. The company is also advancing envudeucitinib in cutaneous lupus erythematosus and Sjogren's disease, along with a separate pipeline candidate targeting neuroinflammatory conditions.

Regulatory Path Forward Will Be the Next Catalyst to Watch

Alumis's near-term trajectory will likely depend on how regulators respond to the company's plan to pursue Phase 3 development in the interferon-high lupus subgroup, alongside continued progress toward the fourth-quarter psoriasis filing. Investors will also be watching for any read-through to the company's broader interferon-driven disease pipeline.